https://www.live-feeds.com/feed/lilly-reports-third-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-regulatory-progress-across-tContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/lilly-reports-third-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-regulatory-progress-across-thttps://www.live-feeds.com/feed/lilly-reports-third-quarter-2026-financial-results-raises-full-year-guidance-and-highlights-regulatory-progress-across-t#u174271Wed, 04 Nov 2026 13:22:08 +0000Eli Lilly reported third-quarter 2026 financial results featuring a 39 percent surge in revenue to $24.4 billion, driven primarily by blockbuster sales of its diabetes and obesity treatments Mounjaro and Zepbound. The pharmaceutical giant raised its full-year financial guidance while noting that third-quarter revenue included approximately $900 million of benefits, such as $410 million in Jardiance milestones and favorable adjustments to rebate and discount estimates. Reported earnings per share for the quarter increased by 16 percent to $7.22. Despite the positive results, the company trimmed